Relevance of CYP2D6 variability in first-episode schizophrenia
patients treated with risperidone

J 2012

Relevance of CYP2D6 variability in first-episode schizophrenia patients treated with risperidone

BARTEČEK, Richard, Jan JUŘICA, Jana ZRUSTOVA, Tomáš KAŠPÁREK, Eva PINDUROVÁ et. al.

Základní údaje

Originální název

Relevance of CYP2D6 variability in first-episode schizophrenia patients treated with risperidone

Autoři

BARTEČEK, Richard (203 Česká republika, domácí), Jan JUŘICA (203 Česká republika, garant, domácí), Jana ZRUSTOVA (203 Česká republika), Tomáš KAŠPÁREK (203 Česká republika, domácí), Eva PINDUROVÁ (203 Česká republika) a Alexandra ŽOURKOVÁ (203 Česká republika)

Vydání

Neuroendocrinology Letters, Stockholm, Maghira and Maas Publications, 2012, 0172-780X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30000 3. Medical and Health Sciences

Stát vydavatele

Švédsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 0.932

Kód RIV

RIV/00216224:14740/12:00060575

Organizační jednotka

Středoevropský technologický institut

UT WoS

000305037700020

Klíčová slova anglicky

Cytochrome P-450; CYP2D6; pharmacogenetics; CYP2D6 analysis; schizophrenia; risperidone

Štítky

ok, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 8. 4. 2013 10:53, Olga Křížová

Anotace

V originále

OBJECTIVE: The objective of this prospective, naturalistic study, conducted in first-episode psychosis patients from a Central-European population, was to assess the utility of Cytochrome P-450 2D6 (CYP2D6) genotype testing under normal clinical setting. METHODS: A total of 35 patients diagnosed for the first time with schizophrenia or acute schizophrenia-like psychotic disorder and treated with risperidone were enrolled in the study. These patients underwent sequentiation of the CYP2D6 gene and evaluations of symptoms and severity of adverse effects using the PANSS and UKU scales, respectively. Doses of antipsychotics and other co-medication were monitored as well. In statistical analysis, Fisher's exact test was used to compare ratios and the Wilcoxon rank-sum test was used in the comparison of continual variables. RESULTS: PM patients showed a significantly lower reduction in psychotic symptoms and a greater severity of psychotic symptoms following risperidone treatment and higher doses of antipsychotics not metabolized by CYP2D6, which were used as co-medication. CONCLUSIONS: Based on these results, patients with the PM genotype experiencing first-episode schizophrenia don't appear to be optimal recipients of risperidone treatment. However, as the main limitation of this study was the relatively small sample-size, replication with a larger scale study is needed to confirm these findings.

Návaznosti

ED1.1.00/02.0068, projekt VaV

Název: CEITEC - central european institute of technology

NS9676, projekt VaV

Název: Vliv farmakogenetických a farmakokinetických faktorů na účinnost a bezpečnost terapie prvních epizod schizofrenie

Investor: Ministerstvo zdravotnictví ČR, Vliv farmakogenetických a farmakokinetických faktorů na účinnost a bezpečnost terapie prvních epizod schizofrenie

Citovat

BARTEČEK, Richard, Jan JUŘICA, Jana ZRUSTOVA, Tomáš KAŠPÁREK, Eva PINDUROVÁ a Alexandra ŽOURKOVÁ. Relevance of CYP2D6 variability in first-episode schizophrenia patients treated with risperidone. Neuroendocrinology Letters. Stockholm: Maghira and Maas Publications, 2012, roč. 33, č. 2, s. 236-244. ISSN 0172-780X.

@article{989157,
   author = {Barteček, Richard and Juřica, Jan and Zrustova, Jana and Kašpárek, Tomáš and Pindurová, Eva and Žourková, Alexandra},
   article_location = {Stockholm},
   article_number = {2},
   keywords = {Cytochrome P-450; CYP2D6; pharmacogenetics; CYP2D6 analysis; schizophrenia; risperidone},
   language = {eng},
   issn = {0172-780X},
   journal = {Neuroendocrinology Letters},
   title = {Relevance of CYP2D6 variability in first-episode schizophrenia patients treated with risperidone},
   url = {http://www.ncbi.nlm.nih.gov/pubmed/22592207},
   volume = {33},
   year = {2012}
}

TY  - JOUR
ID  - 989157
AU  - Barteček, Richard - Juřica, Jan - Zrustova, Jana - Kašpárek, Tomáš - Pindurová, Eva - Žourková, Alexandra
PY  - 2012
TI  - Relevance of CYP2D6 variability in first-episode schizophrenia patients treated with risperidone
JF  - Neuroendocrinology Letters
VL  - 33
IS  - 2
SP  - 236-244
EP  - 236-244
PB  - Maghira and Maas Publications
SN  - 0172780X
KW  - Cytochrome P-450
KW  - CYP2D6
KW  - pharmacogenetics
KW  - CYP2D6 analysis
KW  - schizophrenia
KW  - risperidone
UR  - http://www.ncbi.nlm.nih.gov/pubmed/22592207
L2  - http://www.ncbi.nlm.nih.gov/pubmed/22592207
N2  - OBJECTIVE: The objective of this prospective, naturalistic study, conducted in first-episode psychosis patients from a Central-European population, was to assess the utility of Cytochrome P-450 2D6 (CYP2D6) genotype testing under normal clinical setting. METHODS: A total of 35 patients diagnosed for the first time with schizophrenia or acute schizophrenia-like psychotic disorder and treated with risperidone were enrolled in the study. These patients underwent sequentiation of the CYP2D6 gene and evaluations of symptoms and severity of adverse effects using the PANSS and UKU scales, respectively. Doses of antipsychotics and other co-medication were monitored as well. In statistical analysis, Fisher's exact test was used to compare ratios and the Wilcoxon rank-sum test was used in the comparison of continual variables. RESULTS: PM patients showed a significantly lower reduction in psychotic symptoms and a greater severity of psychotic symptoms following risperidone treatment and higher doses of antipsychotics not metabolized by CYP2D6, which were used as co-medication. CONCLUSIONS: Based on these results, patients with the PM genotype experiencing first-episode schizophrenia don't appear to be optimal recipients of risperidone treatment. However, as the main limitation of this study was the relatively small sample-size, replication with a larger scale study is needed to confirm these findings.
ER  -

BARTEČEK, Richard, Jan JUŘICA, Jana ZRUSTOVA, Tomáš KAŠPÁREK, Eva PINDUROVÁ a Alexandra ŽOURKOVÁ. Relevance of CYP2D6 variability in first-episode schizophrenia patients treated with risperidone. \textit{Neuroendocrinology Letters}. Stockholm: Maghira and Maas Publications, 2012, roč.~33, č.~2, s.~236-244. ISSN~0172-780X.

Podrobný výpis o publikaci